Diego System: Anti-Dia
Authors: Danielle Meunier, MD; Sophia Peng, MD; and Gwen Clarke, MD, FRCPC
Publication date: September 2019
Primary target audiences: Medical laboratory technologists (MLT) in a hospital laboratory, transfusion medicine physicians
- Anti-Dia may be clinically significant.
- Patients with anti-Dia should receive red blood cell units crossmatch compatible by IAT at 37°C for transfusion.
- Patients with sickle cell disease who have anti-Dia should be provided with Dia-negative red blood cell units for transfusion.
Dia is an antigen of the Diego blood group system. The Diego antigens are located on the red blood cell membrane glycoprotein AE1 (also known as Band 3 or CD233), which plays an essential role in cellular gas exchange and anion equilibrium.
Dia is a low-frequency antigen, occurring at 0.01% in most populations. Some groups with higher incidence of Dia include South American Indigenous (2–54%), Japanese (12%), North American Chippewa Indigenous (11%), Chinese (5%), Hispanic (1%) and Polish (0.47%) populations.
Dia was first identified in 1955 when it was implicated in a case of hemolytic disease of the fetus and newborn (HDFN). It is named after Mrs. Diego, the first known producer of anti-Dia.
Anti-Dia is typically immune stimulated (i.e. by transfusion or pregnancy-related red blood cell exposure) IgG1 plus IgG3 and is best detected by IAT at 37°C. Only rare examples of naturally occurring anti-Dia have been reported.
Patient management: Pre-transfusion and prenatal testing
In the context of transfusion, anti-Dia may be clinically significant. It has the ability to cause mild to severe HDFN, but there are only infrequent reports of it being clearly implicated in a hemolytic transfusion reaction. Given the general rarity of Dia antigen, for both current and historically detected anti-Dia, red blood cell units that are crossmatch compatible in the IAT phase at 37°C should be selected for transfusion. Routine donor antigen typing (phenotyping) at Canadian Blood Services does not include Dia typing, therefore a request for Dia-negative red blood cell units results in additional manual phenotyping and/or genotyping. See Table 1 for a summary of recommendations for red blood cell transfusion in patients with non-ABO antibodies.
Patients with sickle cell disease
For sickle cell disease patients without antibodies, most guidelines recommend transfusion of Rh- and Kell-matched units. For those patients with one or more antibodies (current or historical), complete donor phenotype/genotype matching is often recommended. Typically, this matching includes the Rh, Kell, Kidd and Duffy blood group systems along with the S/s antigens. If a sickle cell patient develops an anti-Dia, then Dia-negative units should be provided, along with matching for the full extended phenotype. Given the increased risk of hyperhemolysis in patients with sickle cell disease, this clinical context necessitates full compatibility with the patient’s antigen and antibody profile.
|Patient Antibody||Recommendation for red blood cell transfusion*|
|Anti-Dia||Red blood cell units crossmatch compatible by IAT at 37°C|
|Anti-Wra||Red blood cell units crossmatch compatible by IAT at 37°C|
|Anti-Jsa||Jsa-negative red blood cell units crossmatch compatible by IAT at 37°C|
|Anti-Kpa||Red blood cell units crossmatch compatible by IAT at 37°C|
|Anti-Lea, Anti- Leb, and Anti-Lea||Red blood cell units crossmatch compatible by IAT at 37°C|
|Anti-Lua||Red blood cell units crossmatch compatible by IAT at 37°C|
|Anti-M||Red blood cell units crossmatch compatible by IAT or equivalent using IgG antihuman globulin|
|Anti-Cw||Red blood cell units crossmatch compatible by IAT at 37°C|
|Anti-V||V-negative red blood cell units crossmatch compatible by IAT at 37°C|
* Note: Patients with sickle cell disease who develop any one of the antibodies listed here should be provided with antigen-negative red blood cell units for transfusion.
Meunier D, Peng S, Clarke G. Diego System: Anti-Dia [Internet]. Ottawa: Canadian Blood Services; 2019 Sept 25 [cited YYYY MM DD]. Available from: https://profedu.blood.ca/en/transfusion/best-practices/serological-best-practices
1. Storry JR. Chapter 14: Other blood group systems and antigens; The Diego System. In: Fung M, Grossman B, Hillyer C, Westhoff C, editors. Technical Manual, 18th Ed. Bethesda: AABB; 2014. p. 352-4.
2. Reid M, Lomas Francis C, Olsson M. The Blood Group Antigens Facts Book, 3rd ed. San Diego: Elsevier Science & Technology; 2012. Section II: The blood group systems and antigens; Diego Blood Group System, Dia antigen. p. 388-9.
3. Daniels G. Human Blood Groups, 3rd ed. Oxford: Wiley-Blackwell; 2013. Chapter 10, Diego Blood Group System, 10.3.5: Anti-Dia and -Dib. p. 339-40.
4. NHS Blood and Transplant. NHSBT: Specification SPN214/3: The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion. Available from: https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/14863/spn2144-the-clinical-significance-of-blood-group-alloantibodies-and-the-supply-of-blood-for-transfusion.pdf
5. Davis BA, Allard S, Qureshi A, et al. Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects. Br J Haematol. 2016 Nov 07;176(2):145-330. Available from: http://www.b-s-h.org.uk/guidelines/guidelines/red-cell-transfusion-in-sickle-cell-disease-part-l/
6. The Canadian Haemoglobinopathy Association. Transfusion. In: Consensus Statement on the Care of Patients with Sickle Cell disease in Canada. Version 2.0. Ottawa; 2018. p. 12-20. Available from: https://www.canhaem.org/wp-content/uploads/2018/05/Sickle-Cell-Consensus.pdf